Stipple Bio vs Aleph Alpha

Side-by-side comparison of AI visibility scores, market position, and capabilities

Stipple Bio

ChallengerBioTech

Precision Oncology

Raised $100M oversubscribed Series A (Apr 2026) co-led by RA Capital and a16z Bio. Novel ADC platform targeting tumor-specific epitopes.

About

Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.

Full profile

Aleph Alpha

EmergingAI Infra

Sovereign AI

Aleph Alpha raised €500M+ and pivoted to sovereign AI solutions for European governments, positioning as the leading provider of GDPR-compliant, EU-hosted AI infrastructure for regulated industries.

About

Aleph Alpha is a German AI company building sovereign AI infrastructure for European governments and enterprises that require data sovereignty, GDPR compliance, and AI hosted within EU borders. Its Pharia AI platform provides LLM capabilities deployed on-premises or in EU data centers, serving German federal ministries, European defense agencies, and regulated industries including banking, healthcare, and legal services.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.